[Ip-health] Infojustice Roundup – October 31, 2016

Michael Palmedo mpalmedo at wcl.american.edu
Mon Oct 31 12:15:04 PDT 2016

Infojustice Roundup


AARP, AFL-CIO, Oxfam, Consumers Union & MSF Letter to President Obama, re: Data Exclusivity for Biologics and the TPP

Dear President Obama: As organizations that represent millions of Americans, including consumers, retirees, and patients, and that provide medical care globally, we are concerned about recent reports that your Administration is working behind the scenes to craft Trans-Pacific Partnership (TPP) implementing legislation and possibly enter into side letters that would  mean even more lengthy monopoly protections for biologics than the already onerous provisions in the TPP agreement. It is our understanding that this could bind the United States to a 12-year market exclusivity period for biologics and block the U.S. and other countries from reducing the amount of time expensive biologic drugs are protected from competition from less expensive biosimilar drugs. Click here for more.<http://infojustice.org/archives/37251>


Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers

[Stefan Wiktor, Françoise Renaud and Peter Beyer] ... This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome. It also provides information on the production of new hepatitis C drugs and generic versions worldwide, including  where  the  drugs  are  registered,  where  the  drugs  are  patented  and  where  not,  and  what  opportunities  countries have under the license agreements that were signed by some companies as well as current pricing of all recommended DAAs, including by generic companies all over the world. Click here for more.<http://infojustice.org/archives/37260>


The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia

[Joel Lexchin and Deborah Gleeson] Abstract: The Trans Pacific Partnership Agreement (TPP) is a large regional trade agreement involving twelve countries. It was signed in principle in February 2016 but has not yet been ratified in any of the participating countries. The TPP provisions place a range of constraints on how governments regulate the pharmaceutical sector and set prices for medicines. Click here for more.<http://infojustice.org/archives/37241>

More information about the Ip-health mailing list